UBS raised the firm’s price target on IBM (IBM) to $195 from $170 and keeps a Sell rating on the shares. Weakness in the US dollar and the beginning of the next z17 cycle should be positive for the company’s reported Q2 revenue growth relative to expectations, but it is unlikely to offset a mixed demand picture across both Software and Consulting, the analyst tells investors in a research note. Mixed checks indicate spending across different Consulting verticals, particularly government, is at an increasing risk of funding shortfalls, which risks dampening growth in the quarter, UBS added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IBM:
- IBM Expands Access to Quantum Education and Launches New AI Chips
- New AI Microchips and Servers Do Little for IBM Stock (IBM)
- Don’t Underestimate IBM Stock after Its New Power11 AI Chip Launch
- IBM reveals IBM Power11, next gen of IBM Power servers
- 3 Quantum Computing Stocks with Potential to Beat the Market – 7/7/2025